- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Bioinformatics Software Market Size, Share | CAGR 13.5%
Global Bioinformatics Software Market Size, Share Analysis By Product (Sequence, Genome, Proteomics, Structural, Gene Expression, Simulation, Pathway, Clinical, Integrated), By Application (Genomics, Proteomics, Transcriptomics, Metabolomics, Drug Discovery, Precision Medicine, Diagnostics, Agri-Tech), By Deployment (Cloud, On-Premise, Hybrid, SaaS), By End-User (Pharma, Biotech, Academic, Hospitals, CROs) Region & Key Players-Dynamics, Strategies, Trends & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026-2034) | Largest Region (2025) |
|---|---|---|---|
| USD 10.50 Billion | USD 32.80 Billion | 13.5% | North America, 42.0% |
The Bioinformatics Software Market was valued at USD 9.30 Billion in 2024 and USD 10.50 Billion in 2025. The market is projected to reach USD 32.80 Billion by 2034, expanding at a CAGR of 13.5% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 22.30 Billion over the analysis period. The Bioinformatics Software Market is expanding because the cost of DNA sequencing has fallen by roughly a million-fold since 2003, generating data volumes that overwhelm manual analysis and shifting computational interpretation from a niche capability to core research infrastructure across pharmaceutical, clinical-diagnostic, and academic laboratories.
Bioinformatics Software Market Global Forecast to 2034 (USD)
CAGR OF
13.5%
Bioinformatics Software Market
Get more details on this report -
Demand drivers are anchored to genomic data growth and AI integration. The US National Institutes of Health awarded approximately USD 1.2 Billion to a loop bioinformatics network linking petabytes of genomic data to AI compute through programs such as All of Us. Stanford Medicine reported in January 2022 that a DNA sequencing technique sequenced a complete human genome in roughly eight hours, and per-genome turnaround times have continued to compress. FDA-approved pharmacogenomic drug labels surpassed 400 in 2025, requiring clinical-grade variant interpretation engines that comply with CLIA, CAP, and 21 CFR Part 11 documentation standards.
The regulatory environment is reinforcing software adoption. FDA guidance published in 2024 tightened clinical validity standards for NGS tests, lengthening development cycles and raising data-analysis complexity that buyers solve through validated software platforms. The EU IVDR 2017/746 reclassified bioinformatics-driven assays as Class C devices requiring notified-body assessment, and the EU Horizon Europe research program allocated EUR 1.1 Billion to the European Open Science Cloud in May 2025 to standardize cloud bioinformatics infrastructure across 27 member states. These frameworks pressure laboratories to migrate from open-source pipelines to validated commercial platforms with documented audit trails.
Technology dynamics are restructuring vendor positioning. Cloud-native platforms held 61% of new deployments in 2025 as buyers shifted away from on-premise high-performance computing toward consumption-based models from Illumina BaseSpace, DNAnexus Apollo, and Benchling R&D Cloud. AI and machine learning integration accelerated through 2025-2026, with OpenAI launching GPT-Rosalind for life sciences research in April 2026 and Eli Lilly opening TuneLab to external biotech partners in September 2025 after spending more than USD 1 Billion on the underlying dataset and model training. Multi-omics integration across genomics, transcriptomics, proteomics, and metabolomics is the fastest-rising functional requirement.
Regional concentration is high. North America held 42.0% of revenue in 2025 at approximately USD 4.41 Billion, supported by NIH research obligations exceeding USD 47 Billion in fiscal year 2025 and the densest cluster of pharmaceutical R&D centers globally. Europe held 26.0% on Horizon Europe funding and IVDR-driven validation demand, while Asia Pacific is the fastest-growing region at a CAGR of 16.2% through 2034 on China's National GeneBank, India's biotech Production Linked Incentive scheme, and Japan's reimbursement expansion for 500-plus-gene panels. By 2034, the Bioinformatics Software Market will be defined by vendors that combine AI-native algorithms with cloud-elastic compute and clinical-grade regulatory documentation.
Market Definition & Scope
The Bioinformatics Software Market is defined as the global market for software platforms, applications, and integrated tools that store, process, analyze, visualize, and interpret biological data including genomic sequences, transcriptomic profiles, proteomic spectra, metabolomic signatures, and clinical-genomic associations. The market encompasses sequence analysis platforms, variant interpretation engines, multi-omics integration software, electronic lab notebooks, knowledge management tools, and the cloud-deployed pipelines that operate them across research and clinical settings.
This analysis includes commercial bioinformatics platforms, knowledge-management tools, biological databases, and the recurring software-as-a-service revenue tied to these tools. The scope explicitly excludes hardware-only sequencing instruments, wet-lab consumables, contract bioinformatics services delivered without software licensing, and general-purpose data-analytics platforms not validated for life-sciences workflows. The Bioinformatics Software Market sits within the broader bioinformatics market valued at approximately USD 21.0 Billion in 2025, representing the platforms-and-tools half of total bioinformatics spend.
Key Takeaways
- Market Growth: The Bioinformatics Software Market grew from USD 10.50 Billion in 2025 to a projected USD 32.80 Billion by 2034 at a CAGR of 13.5%, an absolute dollar opportunity of USD 22.30 Billion.
- Segment Dominance (Product): Bioinformatics platforms held the largest revenue share at 49.7% in 2025, anchored by Illumina DRAGEN, QIAGEN CLC Genomics Workbench, and DNAnexus cloud platforms.
- Segment Dominance (Application): Genomics applications captured 42.2% of revenue in 2025, reflecting whole-genome sequencing adoption across the All of Us program, UK Biobank, and China National GeneBank initiatives.
- Driver: DNA sequencing cost declined approximately one-million-fold since 2003, generating data volumes that drove cloud-based bioinformatics platforms to capture 61% of new deployments in 2025.
- Restraint: A persistent talent gap affects more than 50% of pharmaceutical and biotechnology firms in IT and bioinformatics roles, slowing adoption among small and mid-sized laboratories.
- Opportunity: AI in bioinformatics is projected to grow from USD 1.22 Billion in 2026 to USD 4.80 Billion by 2034 at an 18.6% CAGR, opening a software-attached opportunity of approximately USD 3.60 Billion.
- Trend: Multi-omics integration platforms accelerated through 2025-2026 as Illumina launched Connected Multiomics in January 2026 and 10x Genomics released Loupe Browser 8.0 with multi-modal spatial integration in January 2026.
- Regional: North America led the Bioinformatics Software Market at 42.0% share or roughly USD 4.41 Billion in 2025, while Asia Pacific is projected to grow fastest at a 16.2% CAGR through 2034.
Key Insights Summary
- OpenAI launched GPT-Rosalind in April 2026, the first model in its Life Sciences series, delivering leading performance on the BixBench bioinformatics benchmark and outperforming GPT-5.4 on six of eleven LABBench2 research tasks per OpenAI disclosures.
- Benchling closed a USD 200 Million Series F round in November 2025 at a valuation of approximately USD 6.1 Billion, validating cloud-native bioinformatics-software economics and following the August 2025 Benchling acquisition of Sphinx Bio.
- Illumina reported full-year 2025 revenue of USD 4.34 Billion and launched DRAGEN v4.5 software with out-of-the-box oncology applications, plus the Connected Multiomics platform in January 2026 integrating genomics, transcriptomics, and proteomics into one interface.
- QIAGEN completed the acquisition of Bioinformatics Solutions Inc. in February 2025 to strengthen proteomics and mass-spectrometry analytics, and expanded its January 2025 Google Cloud partnership to deliver AI-powered cancer-genomics workflows.
- The US National Institutes of Health awarded approximately USD 1.2 Billion to a loop bioinformatics network linking petabytes of genomic data to AI compute, anchored by supercomputing centers at the University of Wisconsin and Pittsburgh Supercomputing Center.
- The EU Horizon Europe research and innovation program allocated EUR 1.1 Billion in May 2025 to the European Open Science Cloud initiative to create digital research infrastructure for open bioinformatics services across 27 EU member states.
- Eli Lilly launched TuneLab in September 2025, an AI/ML drug-discovery platform built on more than USD 1 Billion of internal training data and opened to external biotechnology partners, with Insilico Medicine signing a Pharma.AI collaboration in November 2025.
Competitive Landscape Overview
The Bioinformatics Software Market is moderately consolidated. The top four vendors, Illumina, Thermo Fisher Scientific, QIAGEN N.V., and Agilent Technologies, collectively held an estimated 45% to 50% of global revenue in 2025 based on aggregated company disclosures. Competition is structured around three vectors: AI model quality on real-world bioinformatics tasks, depth of cloud infrastructure for elastic compute, and breadth of regulatory documentation supporting CLIA, CAP, IVDR, and 21 CFR Part 11 deployments. Cloud-native challengers including DNAnexus, Benchling, and Seven Bridges Genomics are pressuring incumbents on multi-site collaborative workflows that on-premise software cannot support.
Competitive evolution accelerated through 2025-2026. Danaher acquired Genedata in August 2024 for an undisclosed sum, embedding Genedata Profiler and Genedata Screener into the Danaher Life Sciences and Diagnostics platforms. QIAGEN acquired Bioinformatics Solutions Inc. in February 2025 to deepen proteomics analytics, and Benchling closed a USD 200 Million Series F at a USD 6.1 Billion valuation in November 2025. Sequencing-instrument vendors, contract research organizations, and AI-native software start-ups now compete to own the same analytics stack, with Illumina, OpenAI GPT-Rosalind, and Eli Lilly TuneLab all vying for the AI-bio infrastructure layer through 2026.
Competitive Landscape Matrix
| Company Name | Headquarters | Market Position | Key Product / Solution | Geographic Strength | Recent Strategic Move (Trailing 18 Months) |
|---|---|---|---|---|---|
| Illumina, Inc. | USA | Leader | DRAGEN Bio-IT v4.5; BaseSpace Enterprise; Connected Multiomics; NovaCloud Suite | Global, all regions | January 2026 launch of cloud-based Connected Multiomics platform |
| Thermo Fisher Scientific | USA | Leader | Ion Reporter; CarrierSeq; Oncomine analytics; Genexus Dx software | Global, all regions | FY2025 USD 1.4 Billion R&D spend with bioinformatics tools embedded across genomics workflows |
| QIAGEN N.V. | Netherlands | Leader | QIAGEN Digital Insights (QDI); CLC Genomics Workbench; QCI Interpret; Ingenuity Pathway Analysis | Europe, North America | February 2025 acquisition of Bioinformatics Solutions Inc. for proteomics analytics |
| Agilent Technologies | USA | Leader | Alissa Interpret; OpenLab CDS; SureSelect Design Studio | Global pharma and pathology | FY2025 Alissa Interpret upgrades for rare-disease sequence annotation |
| Danaher (Genedata) | USA / Switzerland | Challenger | Genedata Profiler; Genedata Screener; Genedata Biologics | Europe, North America | August 2024 acquisition of Genedata by Danaher for biopharma R&D analytics |
| DNAnexus | USA | Challenger | Precision Health Data Cloud; Apollo; Titan; FDA Sentinel platform | North America, Europe | February 2025 expansion of partnership with Veeva Systems for regulatory collaboration |
| Benchling | USA | Challenger | Benchling R&D Cloud; Benchling Notebook; Sphinx Bio | North America, Europe | November 2025 close of USD 200 Million Series F at USD 6.1 Billion valuation |
| Dassault Systemes (BIOVIA) | France | Niche Player | BIOVIA Pipeline Pilot; Discovery Studio; ONE Lab | Global pharma R&D | FY2025 BIOVIA integration with 3DEXPERIENCE platform across pharmaceutical clients |
| PerkinElmer (Revvity) | USA | Niche Player | Signals Software; OmicsBox integration; Spotfire analytics | Global, North America | Q3 2025 expansion of Signals informatics suite for translational research |
| BGI Genomics | China | Niche Player | ZTRON cloud platform; DNBSEQ analysis pipelines | Asia Pacific, Europe | FY2025 expansion of ZTRON cloud bioinformatics across Asia Pacific clinical labs |
Segmentation Analysis
The Bioinformatics Software Market is segmented across four primary dimensions used by procurement leads and pharmaceutical R&D buyers during platform selection: by product type, by application, by deployment mode, and by end-user. Each dimension carries distinct cost economics, validation requirements, and vendor-lock-in implications that shape multi-year software investment decisions.
By Product Type
Bioinformatics platforms held the largest revenue share at 49.7% in 2025, equivalent to approximately USD 5.22 Billion. Platforms include sequence-analysis engines such as Illumina DRAGEN v4.5, variant-interpretation tools such as QIAGEN QCI Interpret, and integrated R&D environments such as Benchling R&D Cloud. Knowledge-management tools held 25.5% of revenue at approximately USD 2.68 Billion, projected to grow at a 15.3% CAGR through 2034 as pharmaceutical companies consolidate fragmented data assets into graph databases and text-mining engines that surface pathway insights faster than manual curation.
Bio-content management and biological databases held the remaining 24.8% of revenue at approximately USD 2.60 Billion, anchored by curated commercial databases such as QIAGEN Ingenuity Pathway Analysis, Clarivate Cortellis, and Dassault Systemes BIOVIA Pipeline Pilot. Procurement leads conducting bioinformatics software vs in-house platform ROI calculation increasingly favor commercial platforms when annual genome processing exceeds 5,000 samples, because consumption-based pricing eliminates depreciating on-premise cluster amortization.
By Application
Genomics held 42.2% of revenue in 2025 at approximately USD 4.43 Billion, anchored by whole-genome and exome sequencing across NIH All of Us, UK Biobank, and population-scale projects. Transcriptomics held 14.5% at roughly USD 1.52 Billion, while proteomics held 13.8% at USD 1.45 Billion and is projected to grow fastest at a 14.4% CAGR through 2034 on mass-spectrometry advances quantifying more than 10,000 proteins per sample. Cheminformatics and drug design held 11.5%, metabolomics held 10.5%, and other applications including molecular phylogenetics held the residual 7.5%. Procurement teams selecting between platforms increasingly require multi-omics integration as the default rather than a premium add-on.
By Deployment Mode
Cloud-based deployment held 61.4% of revenue in 2025 at approximately USD 6.45 Billion, reflecting buyer migration from on-premise high-performance computing toward consumption-based AWS, Microsoft Azure, and Google Cloud bioinformatics environments. On-premise deployment held 30.0% at roughly USD 3.15 Billion, concentrated in defense, government, and clinical-laboratory segments with strict data-residency requirements. Hybrid deployment held 8.6% and is projected to grow at an 11.5% CAGR through 2034 as pharmaceutical R&D teams balance regulatory data residency with elastic compute for AI model training.
By End-User
Pharmaceutical and biotechnology companies represented 48.8% of end-user demand in 2025 at approximately USD 5.12 Billion, driven by drug-discovery target identification, biomarker analysis, and translational research workflows. Academic and research institutes accounted for 22.5% at approximately USD 2.36 Billion, supported by NIH and Horizon Europe grant funding. Hospitals and clinical laboratories held 16.5% and are projected to grow fastest at an 11.7% CAGR through 2034 on validated CLIA-compliant variant-interpretation pipelines, while contract research organizations held 12.2% at approximately USD 1.28 Billion. Procurement checklists across all end-users converge on five evaluation criteria: AI-model accuracy on internal benchmarks, cloud-elastic compute economics, IVDR and CLIA validation depth, multi-omics integration breadth, and total cost of ownership over five years.
Regional Analysis
The Bioinformatics Software Market spans five regions with distinct funding mechanisms, regulatory frameworks, and pharmaceutical R&D concentrations. Regional revenue shares in 2025 were North America at 42.0%, Europe at 26.0%, Asia Pacific at 24.0%, Latin America at 4.0%, and Middle East and Africa at 4.0%.
North America
North America led the Bioinformatics Software Market at 42.0% share or approximately USD 4.41 Billion in 2025, anchored by the United States, Canada, and Mexico. The US installed base alone is estimated at USD 3.95 Billion and is supported by NIH research obligations exceeding USD 47 Billion in fiscal year 2025, plus the USD 1.2 Billion NIH loop bioinformatics network award linking petabytes of genomic data to AI compute. FDA 2024 guidance tightened clinical validity standards for NGS tests, raising data-analysis complexity that buyers solve through validated software platforms. Illumina, Thermo Fisher, and DNAnexus dominate domestic revenue, and Benchling closed a USD 200 Million Series F at a USD 6.1 Billion valuation in November 2025.
Europe
Europe held 26.0% of the Bioinformatics Software Market in 2025, equivalent to approximately USD 2.73 Billion. The EU Horizon Europe program allocated EUR 1.1 Billion in May 2025 to the European Open Science Cloud, building digital research infrastructure across 27 member states. The EU IVDR 2017/746 reclassified bioinformatics-driven assays as Class C devices, requiring notified-body assessment that drives platform validation revenue. Genedata, headquartered in Basel, was acquired by Danaher in August 2024 to anchor pharmaceutical R&D analytics, and the Swiss Institute of Bioinformatics shared AI-bioinformatics innovations in September 2025 across Geneva, Lausanne, and Basel research clusters.
Asia Pacific
Asia Pacific captured 24.0% of revenue in 2025 at approximately USD 2.52 Billion and is projected to expand at the fastest regional CAGR of 16.2% through 2034. China leads demand through the China Precision Medicine Initiative, China National GeneBank, and BGI Genomics ZTRON cloud platform. Japan broadened reimbursement for 500-plus-gene panels through the Pharmaceuticals and Medical Devices Agency, accelerating hospital adoption. India incubates start-ups that localize pipelines for South Asian haplotypes, while South Korea's biosimilar industry adopts bioinformatics tools for comparability protocols. HaploX Group established its Japanese subsidiary HaploX JAPAN K.K. in February 2025.
Latin America
Latin America accounted for 4.0% of the Bioinformatics Software Market in 2025, approximately USD 0.42 Billion, with Brazil, Mexico, and Argentina as the largest country markets. Mexico's biosimilar producers adopt bioinformatics tools for comparability protocols, while Brazil's Conselho Nacional de Desenvolvimento Cientifico e Tecnologico funds genomics research at major federal universities. Foreign-exchange volatility and limited cloud-region availability remain the primary procurement frictions, though AWS and Microsoft Azure expanded Sao Paulo and Mexico City regions through 2025.
Middle East and Africa
Middle East and Africa held 4.0% of the Bioinformatics Software Market in 2025, equivalent to approximately USD 0.42 Billion. Saudi Arabia, the UAE, and Israel lead demand, supported by Saudi Vision 2030 healthcare investments and the UAE Genome Program targeting one million Emirati genomes. Israel's biotech cluster around Weizmann Institute of Science and Technion anchors regional software development, while South Africa's H3Africa Consortium funds population-genomics infrastructure. King Faisal Specialist Hospital in Riyadh and Cleveland Clinic Abu Dhabi expanded validated bioinformatics deployments through 2025.
Country Analysis
Country-level dynamics within the Bioinformatics Software Market vary on funding mechanism, regulatory pathway, and domestic vendor presence. The four most relevant national markets in 2025 are the United States, China, Germany, and the United Kingdom, which together account for approximately 65% of global revenue.
United States
The United States Bioinformatics Software Market was valued at approximately USD 3.95 Billion in 2025 and is projected to grow at a country-specific CAGR of 14.0% through 2034. Federal demand drivers include NIH research obligations exceeding USD 47 Billion in fiscal year 2025, the USD 1.2 Billion NIH loop bioinformatics network award, and the All of Us research program targeting one million participants. State-level cluster funding in California, Massachusetts, and North Carolina supports private vendors. Domestic anchors Illumina, Thermo Fisher, DNAnexus, and Benchling together hold an estimated 60% of US revenue, and Benchling raised USD 200 Million Series F at USD 6.1 Billion valuation in November 2025.
China
China's Bioinformatics Software Market reached an estimated USD 1.20 Billion in 2025 and is forecast to grow at a country-specific CAGR of 17.5% through 2034, the fastest among major economies. The 14th Five-Year Plan for Bioeconomy and the China Precision Medicine Initiative prioritize domestic genomics infrastructure. BGI Genomics operates the ZTRON cloud bioinformatics platform and the China National GeneBank, anchoring domestic supply alongside Burning Rock Biotech and AmoyDx. State-sponsored sequencing capacity scales vertically integrated analytics platforms, and Chinese cloud providers Alibaba Cloud and Tencent Cloud are emerging as bioinformatics deployment alternatives to AWS and Microsoft Azure.
Germany
Germany's Bioinformatics Software Market was valued at approximately USD 0.78 Billion in 2025 and is projected to grow at a country-specific CAGR of 12.4% through 2034. The Bundesministerium fuer Bildung und Forschung funds genomics research through the de.NBI national bioinformatics infrastructure, and German pharma clusters in Heidelberg, Munich, and Berlin anchor demand. Domestic and Europe-headquartered vendors include QIAGEN, Genedata (Danaher subsidiary), Biomax Informatics AG, and Intrexon Bioinformatics Germany. EU IVDR compliance is driving validation-software revenue across pathology and clinical-genomics laboratories.
United Kingdom
The United Kingdom Bioinformatics Software Market reached approximately USD 0.62 Billion in 2025 and is forecast to grow at a country-specific CAGR of 13.2% through 2034. Genomics England operates the largest national whole-genome sequencing program globally, and the UK Biobank holds genomic and clinical data on 500,000 volunteers analyzed through DNAnexus partnerships. NHS England's National Genomic Test Directory anchors clinical-genomics software adoption. Domestic vendors include Source BioScience, Fios Genomics, and Eagle Genomics, and the UK government allocated GBP 175 Million through 2025 to bioinformatics research infrastructure.
Bioinformatics Software Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
13.5%
The Forecast Market
Size for 2034 in USD:
$USD 32.80 B
Get more details on this report -
Key Market Segments
By Product Type
- Sequence Analysis Software
- Genome Annotation Software
- Proteomics Analysis Software
- Structural Bioinformatics Software
- Gene Expression Analysis Software
- Molecular Modeling and Simulation Software
- Pathway Analysis Software
- Clinical Bioinformatics Software
- Integrated Bioinformatics Platforms
- Others
By Application
- Genomics
- Proteomics
- Transcriptomics
- Metabolomics
- Drug Discovery and Development
- Precision Medicine
- Clinical Diagnostics
- Agricultural Biotechnology
- Microbial Genomics
- Biomarker Discovery
- Others
By Deployment Mode
- Cloud-Based
- On-Premises
- Hybrid Deployment
- Software-as-a-Service (SaaS)
- Web-Based Platforms
- Others
By End-User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Hospitals and Diagnostic Laboratories
- Contract Research Organizations (CROs)
- Clinical Research Organizations
- Government Research Organizations
- Agricultural and Environmental Research Organizations
- Forensic Laboratories
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 10.50 B |
| Forecast Revenue (2034) | USD 32.80 B |
| CAGR (2025-2034) | 13.5% |
| Historical data | 2021-2024 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Product Type, (Sequence Analysis Software, Genome Annotation Software, Proteomics Analysis Software, Structural Bioinformatics Software, Gene Expression Analysis Software, Molecular Modeling and Simulation Software, Pathway Analysis Software, Clinical Bioinformatics Software, Integrated Bioinformatics Platforms, Others), By Application, (Genomics, Proteomics, Transcriptomics, Metabolomics, Drug Discovery and Development, Precision Medicine, Clinical Diagnostics, Agricultural Biotechnology, Microbial Genomics, Biomarker Discovery, Others), By Deployment Mode, (Cloud-Based, On-Premises, Hybrid Deployment, Software-as-a-Service (SaaS), Web-Based Platforms, Others), By End-User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Diagnostic Laboratories, Contract Research Organizations (CROs), Clinical Research Organizations, Government Research Organizations, Agricultural and Environmental Research Organizations, Forensic Laboratories, Others) |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | ILLUMINA, INC., THERMO FISHER SCIENTIFIC, QIAGEN N.V., AGILENT TECHNOLOGIES, DANAHER (GENEDATA), DNANEXUS, BENCHLING, DASSAULT SYSTEMES (BIOVIA), PERKINELMER (REVVITY), BGI GENOMICS, EUROFINS SCIENTIFIC, BIO-RAD LABORATORIES, SEVEN BRIDGES GENOMICS, PARTEK, DNASTAR, BIOMAX INFORMATICS, SOPHIA GENETICS, 10X GENOMICS, OXFORD NANOPORE TECHNOLOGIES, PACIFIC BIOSCIENCES, Others |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Bioinformatics Software Market?
The Global Bioinformatics Software Market was valued at USD 9.30 Billion in 2024 and USD 10.50 Billion in 2025, and is projected to reach USD 32.80 Billion by 2034, growing at a CAGR of 13.5% from 2026 to 2034. Market growth is driven by genomic sequencing, AI-powered bioinformatics, precision medicine, and next-generation sequencing (NGS).
Who are the major players in the Bioinformatics Software Market?
ILLUMINA, INC., THERMO FISHER SCIENTIFIC, QIAGEN N.V., AGILENT TECHNOLOGIES, DANAHER (GENEDATA), DNANEXUS, BENCHLING, DASSAULT SYSTEMES (BIOVIA), PERKINELMER (REVVITY), BGI GENOMICS, EUROFINS SCIENTIFIC, BIO-RAD LABORATORIES, SEVEN BRIDGES GENOMICS, PARTEK, DNASTAR, BIOMAX INFORMATICS, SOPHIA GENETICS, 10X GENOMICS, OXFORD NANOPORE TECHNOLOGIES, PACIFIC BIOSCIENCES, Others
Which segments covered the Bioinformatics Software Market?
By Product Type, (Sequence Analysis Software, Genome Annotation Software, Proteomics Analysis Software, Structural Bioinformatics Software, Gene Expression Analysis Software, Molecular Modeling and Simulation Software, Pathway Analysis Software, Clinical Bioinformatics Software, Integrated Bioinformatics Platforms, Others), By Application, (Genomics, Proteomics, Transcriptomics, Metabolomics, Drug Discovery and Development, Precision Medicine, Clinical Diagnostics, Agricultural Biotechnology, Microbial Genomics, Biomarker Discovery, Others), By Deployment Mode, (Cloud-Based, On-Premises, Hybrid Deployment, Software-as-a-Service (SaaS), Web-Based Platforms, Others), By End-User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Diagnostic Laboratories, Contract Research Organizations (CROs), Clinical Research Organizations, Government Research Organizations, Agricultural and Environmental Research Organizations, Forensic Laboratories, Others)
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Bioinformatics Software Market
Published Date : 29 Jun 2026 | Formats :Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date